Cephalon Submits NUVIGIL Supplemental New Drug Application for the Treatment of Excessive Sleepiness Associated with Jet La...(acturing development and capabilities ma...),Health

Date:6/30/2009

acturing development and capabilities, market prospects for its products, sales and earnings guidance, and other statements regarding matters that are not historical facts. You may identify some of these forward-looking statements by the use of words in the statements such as "anticipate," "estimate," "expect," "project," "intend," "plan," "believe" or other words and terms of similar meaning. Cephalon's performance and financial results could differ materially from those reflected in these forward-looking statements due to general financial, economic, regulatory and political conditions affecting the biotechnology and pharmaceutical industries as well as more specific risks and uncertainties facing Cephalon such as those set forth in its reports on Form 8-K, 10-Q and 10-K filed with the U.S. Securities and Exchange Commission. Given these risks and uncertainties, any or all of these forward-looking statements may prove to be incorrect. Therefore, you should not rely on any such factors or forward-looking statements. Furthermore, Cephalon does not intend to update publicly any forward-looking statement, except as required by law. The Private Securities Litigation Reform Act of 1995 permits this discussion.

    Contacts:
    Media:                         Investor Relations:
    Candace Steele                 Chip Merritt
    610-727-6231 (office)          610-738-6376 (office)
    csteele@cephalon.com           cmerritt@cephalon.com

'/>"/>

SOURCE Cephalon, Inc. Copyright©2009 PR Newswire. All rights reserved

1 GOOD

Page: 1 2 3 4
Related medicine technology :

1. Cephalon Provides Clinical Update on Lestaurtinib in Relapsed Acute Myelogenous Leukemia
2. Cephalon Announces Positive Results from a Phase Three Study of NUVIGIL in Jet Lag Disorder
3. Cephalon Announces Positive Results From a Phase Two Study of NUVIGIL in Bipolar Depression
4. Cephalon Signs Option Agreement to Acquire Ception Therapeutics
5. Cephalon Receives Complete Response Letter Regarding Request for Expanded FENTORA Label for Non-Cancer Breakthrough Pain
6. Journal of Clinical Oncology Publishes Study of Cephalon Medication TREANDA Plus Rituximab in Relapsed Non-Hodgkins Lymphoma
7. Cephalon Announces Positive Results from Its Pivotal Study of TREANDA in Patients with Non-Hodgkins Lymphoma
8. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
9. PharmAthene Submits Proposal to BARDA in Response to Broad Agency Announcement for Advanced Research and Development for Valortim(R)
10. PharmAthene Submits SparVax(TM) Regulatory Strategy to FDA
11. Human Genome Sciences Submits Biologics License Application to FDA for ABthrax(TM)